Clinical Trial Update: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating mechanisms of resistance to osimertib in EGFR-mutated, non-pretreated advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertib (osimertinib)

Snippet

Sponsor: Nantes University Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN